Physician profile
David C Marzulo
NPI 1699771600
$38,281.38
in general payments reported to CMS, 2019-2025
79 companies · $3,162 in 2025
The $3,162 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,277 · 2020: $4,040 · 2021: $7,193 · 2022: $6,259 · 2023: $6,133 · 2024: $5,217 · 2025: $3,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $300 · Education: $33.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,178.19 |
| Consulting Fee | $300.00 |
| Education | $33.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $3,856.51 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Abbvie INC. | $3,780.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $3,294.59 | 2019-2025 | |
| Ucb, INC. | $2,837.54 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Emd Serono, INC. | $2,096.30 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $1,802.99 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Lilly USA, LLC | $1,476.59 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Acadia Pharmaceuticals INC | $1,267.04 | 2019-2024 | Nuplazid |
| Pfizer INC. | $1,148.85 | 2020-2025 | |
| Amgen INC. | $990.93 | 2019-2024 | Uplizna |
| Genzyme Corporation | $964.99 | 2019-2023 | |
| Allergan, INC. | $961.28 | 2019-2022 | |
| Mdd US Operations, LLC | $705.33 | 2019-2022 | |
| Lundbeck LLC | $691.23 | 2019-2025 | Vyepti, Rexulti |
| Horizon Therapeutics Plc | $688.93 | 2021-2023 | Uplizna |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Marzulo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.